Cancer Therapies Market in Europe 2022-2026
Technavio has been monitoring the cancer therapies market in Europe and it is poised to grow by $ 34.71 bn during 2022-2026 progressing at a CAGR of 7.92% during the forecast period. Our report on the cancer therapies market in Europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased prevalence of cancer and the introduction of combination therapies.
The cancer therapies market in Europe analysis includes the type segment and geographic landscape.
Technavio's cancer therapies market in Europe is segmented as below:
By Type
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Others
By Geographical Landscape
- Germany
- UK
- France
- Italy
- Rest of Europe
This study identifies the increasing awareness about effective therapies in patient populationas one of the prime reasons driving the cancer therapies market growth in Europe during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on cancer therapies market in Europe covers the following areas:
- Cancer therapies market sizing
- Cancer therapies market forecast
- Cancer therapies market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer therapies market vendors in Europe that include Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc. Also, the cancer therapies market in Europe analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Companies MentionedAmgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc.